These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 29484273)
41. Molecular, Electrophysiological, and Ultrasonographic Differences in Selected Immune-Mediated Neuropathies with Therapeutic Implications. Dziadkowiak E; Nowakowska-Kotas M; Rałowska-Gmoch W; Budrewicz S; Koszewicz M Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298132 [TBL] [Abstract][Full Text] [Related]
42. Plasmacytosis is a common immune signature in patients with MMN and CIDP and responds to treatment with IVIg. Korporal-Kuhnke M; Haas J; Schwarz A; Jarius S; Wildemann B J Neuroimmunol; 2015 Jan; 278():60-8. PubMed ID: 25595253 [TBL] [Abstract][Full Text] [Related]
43. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy. Hughes RA Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S32-6. PubMed ID: 12690659 [TBL] [Abstract][Full Text] [Related]
44. Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins. Ritter C; Bobylev I; Lehmann HC J Neuroinflammation; 2015 Aug; 12():148. PubMed ID: 26268846 [TBL] [Abstract][Full Text] [Related]
45. Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects. Rajabally YA J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):631-7. PubMed ID: 24124042 [TBL] [Abstract][Full Text] [Related]
46. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842 [TBL] [Abstract][Full Text] [Related]
47. Immune-Mediated Neuropathies. Gwathmey KG; Smith AG Neurol Clin; 2020 Aug; 38(3):711-735. PubMed ID: 32703478 [TBL] [Abstract][Full Text] [Related]
58. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Darabi K; Abdel-Wahab O; Dzik WH Transfusion; 2006 May; 46(5):741-53. PubMed ID: 16686841 [TBL] [Abstract][Full Text] [Related]
60. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years. Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]